CGON
NASDAQCG Oncology Inc.
Price$59.83-1.63 (-2.66%)
01:30 PM06:45 PM
News · 26 weeks460%
2026-04-192026-10-11
Mix1290d
- Other5(42%)
- SEC Filings4(33%)
- Insider2(17%)
- Leadership1(8%)
Latest news
25 items- SECSEC Form 144 filed by CG Oncology Inc.144 - CG Oncology, Inc. (0001991792) (Subject)
- PRCG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial OfficerDALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical executive with more than 20 years of commercial leadership experience, Ms. Kalofonos will lead the Company's commercial strategy and execution as CG Oncology advances toward the potential launch of cretostimogene grenadenorepvec and continues to establish itself as a leader in bladder cancer. "Isabel’s appointment reflects our commitment to ensuring we are well positioned to bring cretostimogene to as many patients as possible upon approval," said Arthur Kuan, Chairman and Chief Executive Officer
- INSIDERDirector Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $72,980 worth of shares (1,000 units at $72.98) as part of a pre-agreed trading plan (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- PRCG Oncology to Present at Upcoming Investor Conferences in SeptemberDALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows: Cantor Fitzgerald Global Healthcare ConferencePresentation Time: Wednesday, September 9, 2026 at 8:00am ET Morgan Stanley Global Healthcare ConferencePresentation Time: Monday, September 14, 2026 at 4:50pm ET Interested parties may access the live audio webcast for the conferences from the Investor Relations section of the company's we
- INSIDERDirector Post Leonard E sold $74,540 worth of shares (1,000 units at $74.54) as part of a pre-agreed trading plan and exercised 1,000 shares at a strike of $0.60 (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.SCHEDULE 13G/A - CG Oncology, Inc. (0001991792) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.SCHEDULE 13G/A - CG Oncology, Inc. (0001991792) (Subject)
- SECSEC Form 10-Q filed by CG Oncology Inc.10-Q - CG Oncology, Inc. (0001991792) (Filer)
- SECCG Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - CG Oncology, Inc. (0001991792) (Filer)
- PRCG Oncology Reports Second Quarter 2026 Financial Results and Provides Business UpdatesPIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected fourth quarter 2026 Phase 3 BOND-003 Cohort C Study Results published in The Lancet Oncology, further validating the strength of the clinical evidence supporting cretostimogene Well-positioned to deliver on key milestones with approximately $1.0 billion cash, cash equivalents and marketable securities sufficient to fund operations through 2029 DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today reported financial results for the second quarter ended June 30
- SECSEC Form 424B5 filed by CG Oncology Inc.424B5 - CG Oncology, Inc. (0001991792) (Filer)
- PRCG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet OncologyDALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced the publication of results from the pivotal Phase 3 BOND-003 Cohort C trial evaluating cretostimogene grenadenorepvec monotherapy in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without Ta/T1 disease, in The Lancet Oncology. "Patients with BCG-unresponsive NMIBC often face the difficult decision between pursuing additional bladder-sparing therapies or undergoing a severe, life-altering cystectomy," said Mark D. Tyson II, M.D., M.P.H., Mayo Clinic, and lead author of the publication. "The results f
- INSIDERDirector Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $71,170 worth of shares (1,000 units at $71.17) as part of a pre-agreed trading plan (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERDirector Mulay James exercised 24,165 shares at a strike of $26.63 and sold $1,816,241 worth of shares (24,165 units at $75.16) as part of a pre-agreed trading plan (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- SECSEC Form 144 filed by CG Oncology Inc.144 - CG Oncology, Inc. (0001991792) (Subject)
- SECSEC Form 144 filed by CG Oncology Inc.144 - CG Oncology, Inc. (0001991792) (Subject)
- INSIDERDirector Liu Brian Guan-Chyun bought $24,814,454 worth of shares (371,085 units at $66.87) (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERDirector Post Leonard E exercised 5,000 shares at a strike of $0.60 and sold $350,000 worth of shares (5,000 units at $70.00) as part of a pre-agreed trading plan (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- PRThe New War on Cancer: Four Public Companies Helping Lead a Medical RevolutionDENVER, June 25, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Cancer treatment is undergoing one of the most significant transformations in modern medical history. For decades, physicians relied primarily on surgery, radiation, and chemotherapy. While those therapies have saved countless lives, a new generation of biotechnology companies is working to make cancer treatment smarter, more targeted, and potentially more effective. Rather than simply attacking rapidly dividing cells, researchers are developing therapies designed to identify specific genetic mutations, harness the immune system, and deliver treatments directly to cancer cells while minimizing damage to healthy tissue. Seve
- SECSEC Form 144 filed by CG Oncology Inc.144 - CG Oncology, Inc. (0001991792) (Subject)
- INSIDERDirector Post Leonard E sold $325,000 worth of shares (5,000 units at $65.00) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $0.60 (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- SECSEC Form 144 filed by CG Oncology Inc.144 - CG Oncology, Inc. (0001991792) (Subject)
- INSIDERDirector Mulay James exercised 1,964 shares at a strike of $9.64 and sold $118,076 worth of shares (1,964 units at $60.12) as part of a pre-agreed trading plan (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- SECSEC Form 8-K filed by CG Oncology Inc.8-K - CG Oncology, Inc. (0001991792) (Filer)
- INSIDERSEC Form 4 filed by Director Liu Brian Guan-Chyun4 - CG Oncology, Inc. (0001991792) (Issuer)
CGON FAQ
6 questionsWhere does CGON stock trade?
CG Oncology Inc. (CGON) is listed on NASDAQ.What sector and industry is CGON in?
CG Oncology Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did CG Oncology Inc. go public?
CG Oncology Inc. (CGON) completed its IPO in 2024.What are analysts saying about CGON?
CG Oncology Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-05-19. Recent price targets range from $2300.00 to $4100.00.What companies are similar to CGON?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare CGON side-by-side with any of them on Quantisnow.How can I track CGON on Quantisnow?
Quantisnow aggregates CG Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CGON to receive live email and push alerts on every new disclosure.